Ziphius Vaccines

Executive Summary

Ziphius Vaccines is a Belgian biotechnology company leveraging self-amplifying RNA (saRNA) technology to develop vaccines and therapies for infectious diseases, rare diseases, and oncology. Founded in 2020 and based in Ghent, the company aims to unlock the potential of saRNA, which offers advantages such as dose-sparing and potent immune responses. As a private, early-stage biotech, Ziphius is positioned to address significant unmet medical needs but currently lacks disclosed pipeline details, funding history, or valuation. The company’s success hinges on advancing its saRNA platform through preclinical and clinical development, securing partnerships, and raising capital to fund R&D. With no recent catalysts or updates, the company remains under the radar, but its innovative technology could attract interest from larger pharma collaborators.

Upcoming Catalysts (preview)

• Q4 2026Series A Financing Round40% success
• Q2 2026Preclinical Data Release for Lead saRNA Vaccine Candidate50% success
• Q3 2026Partnership or Licensing Agreement for Infectious Disease Program30% success